Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04959266 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib
A Phase 1 study, sponsored by AstraZeneca.
- Terminated
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT04959266 is a Phase 1 study that was terminated before completion, run by AstraZeneca. The registered enrollment target is 5 participants.
The verdict
NCT04959266, a Phase 1 study, was terminated before completion, sponsored by AstraZeneca.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.
Interventions
- DRUG Itraconazole
- DRUG Omeprazole
- DRUG Adavosertib
- DRUG Rifampicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-06-28 |
| Est. Completion | 2022-06-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04959266
The ClinicalTrials.gov registry entry for NCT04959266 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Itraconazole is the first listed.
NCT04959266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04959266 about?
NCT04959266 is a clinical study titled "A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib". This is a Phase 1, open-label, non-randomised, 3-arm (A, B, and C), drug-drug interaction study in patients with advanced solid tumours.
What is the current status of trial NCT04959266?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2021-06-28. Estimated completion is 2022-06-01.
What interventions are being tested in trial NCT04959266?
The interventions under investigation include: Itraconazole (DRUG), Omeprazole (DRUG), Adavosertib (DRUG), Rifampicin (DRUG).
Who is sponsoring clinical trial NCT04959266?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.